Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New cell therapy trial offers hope for young leukemia patients

NCT ID NCT07464951

First seen Mar 18, 2026 · Last updated May 25, 2026 · Updated 12 times

Summary

This early-stage trial tests a new treatment called CART123 for children and young adults (up to age 29) with acute myeloid leukemia (AML) that has returned or not responded to standard therapy. The treatment uses the patient's own immune cells, modified to target and kill leukemia cells. Some participants will also receive a drug called ruxolitinib to see if it makes the cell therapy work better. The main goals are to check safety and find the best dose.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania, 19104, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.